CLR 3001

Drug Profile

CLR 3001

Alternative Names: CLR3001

Latest Information Update: 12 Feb 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Clera
  • Class Antidementias; Antidepressants; Small molecules
  • Mechanism of Action Dopamine receptor modulators; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cognition disorders
  • Discontinued Major depressive disorder

Most Recent Events

  • 12 Feb 2016 CLR 3001 is still in phase IIa trial for Cognition disorder in Canada (Clera pipeline, February 2016)
  • 21 Jan 2014 CLR 3001 is available for licensing as of 01 Jan 2014. http://www.clera.com
  • 01 Jan 2014 Discontinued - Phase-II for Major depressive disorder in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top